---
title: "Novartis shareholder urges board shake-up after trial setbacks; CMS pursues more drug-pricing deals"
id: "stat-news-0-stat-pharmalittle-we-re-reading-about-a-novartis-investor-seeking-a-shake-up-a"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-pharmalittle-we-re-reading-about-a-novartis-investor-seeking-a-shake-up-a"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "STAT News"
source_url: "https://www.statnews.com/pharmalot/2026/09/10/novartis-investor-seeking-shake-up-gilead-uk-hiv-setback/?utm_campaign=rss"
published_at: "2026-09-10T13:09:22.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Novartis shareholder urges board shake-up after trial setbacks; CMS pursues more drug-pricing deals
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-pharmalittle-we-re-reading-about-a-novartis-investor-seeking-a-shake-up-a
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/pharmalot/2026/09/10/novartis-investor-seeking-shake-up-gilead-uk-hiv-setback/?utm_campaign=rss)
- **Published At:** 2026-09-10T13:09:22.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This Pharmalittle column (Ed Silverman, Sept. 10, 2026) summarizes recent pharma- and policy-related developments, including corporate governance pressure at Novartis, clinical trial failures, federal drug-pricing negotiations, and a legal development affecting access to **mifepristone**. - A major Novartis shareholder called for a board shake-up after the company’s shares plunged following two clinical disappointments. The shareholder cited weak oversight of acquisitions and deals. - The Novartis clinical setbacks included a late-stage failure of a muscle-wasting disorder drug acquired via the company’s $12 billion takeover of Avidity, and disappointing results for the cardiovascular drug **pelacarsen**. - The shareholder raising concerns was David Samra of Artisan Partners and founding partner of International Value Group; reporting on the shareholder action was attributed to Reuters. - U.S. Centers for Medicare and Medicaid Services Administrator Mehmet Oz said the Trump administration is pursuing additional **drug-pricing** deals with pharmaceutical companies, according to Bloomberg. - Officials have announced more than two dozen voluntary pricing agreements to date; these deals are bespoke but generally involve companies lowering prices charged to public programs and launching new drugs at prices similar to other developed nations in exchange for tariff relief, per the source. - A U.S. appeals court panel reportedly appeared skeptical of Louisiana’s bid to curtail access to mifepristone; the column includes that legal item in its roundup. - The article is part of the Pharmalittle newsletter and is flagged as a STAT+ exclusive; the longer STAT+ story is paywalled. - The column mixes brief news items, sourcing from Reuters and Bloomberg, and the author’s usual newsletter/column framing; specific additional details from the paywalled STAT+ exclusive were not included in the free portion of the source.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/pharmalot/2026/09/10/novartis-investor-seeking-shake-up-gilead-uk-hiv-setback/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/pharmalot/2026/09/10/novartis-investor-seeking-shake-up-gilead-uk-hiv-setback/?utm_campaign=rss) [Physicians](https://www.statnews.com/topic/physicians/) [Congress](https://www.statnews.com/topic/congress/) [research](https://www.statnews.com/topic/research/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)Newsletter[Pharmalot](https://www.statnews.com/category/pharma/pharmalot/) # Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more ## U.S. appeals court appeared skeptical of Louisiana bid to curtail access to ​mifepristone * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/pharmalot/2026/09/10/novartis-investor-seeking-shake-up-gilead-uk-hiv-setback/?utm_campaign=rss) ![an anthropomorphized red and blue pill illustrated in the style of the famous american gothic painting](https://www.statnews.com/wp-content/uploads/2015/11/PHARMALOT_LITTLE-copy-645x645.jpg) Alex Hogan/STAT ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) Sept. 10, 2026 Pharmalot Columnist, Senior Writer ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 1. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") 2. [](https://x.com/Pharmalot "X") ed.silverman@statnews.com Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning [Pharmalittle newsletter](https://www.statnews.com/signup/pharmalittle/) and the afternoon [Pharmalot newsletter](https://www.statnews.com/signup/pharmalot/). Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. As for the official mascots, they are happily snoozing in their respective corners. As for us, we are firing up the coffee kettle for another cup of stimulation. Our choice today is tiramisu. Of course, you are invited to join us. For the full experience, we are now hawking replicas — [take a look](https://store.bostonglobe.com/collections/stat-news/products/pharmalot-mug). Meanwhile, here are a few items of interest. As always, do keep in touch. We appreciate feedback, criticism, and tips. … **A major Novartis shareholder has called for a shake-up of the drugmaker’s board to improve corporate governance after its shares suffered a record fall this week ​following back-to-back trial setbacks** , [Reuters](https://www.reuters.com/world/major-novartis-shareholder-calls-board-shake-up-after-drug-trial-setbacks-2026-09-10/) tells us. David Samra, managing director at Artisan Partners and founding partner of International Value ‌Group, said successive chairmen had failed Novartis on acquisitions and that the company needed to change how it oversees deals. In recent days, Novartis disclosed a muscle-wasting disorder drug acquired through its $12 billion takeover ​of Avidity failed a late-stage study, and results from heart drug pelacarsen disappointed investors. Advertisement **U.S. Centers for Medicare and Medicaid Services Administrator Mehmet Oz says the Trump administration is pursuing additional drug-pricing deals with pharmaceutical companies** , [Bloomberg News](https://www.bloomberg.com/news/articles/2026-09-09/trump-administration-working-on-more-drug-pricing-deals-oz-says) reports. Officials have so far announced more than two dozen voluntary agreements with pharmaceutical companies. Each of the agreements is bespoke, but companies generally have agreed to lower the prices they charge public programs for medicines and to launch new drugs at prices similar to those paid by other developed nations in exchange for relief from tariffs. [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [pharmalittle](https://www.statnews.com/topic/pharmalittle/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 1. [](https://x.com/Pharmalot "X") 2. 3. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") Pharmalot Columnist, Senior Writer 1. [](https://x.com/Pharmalot "X") 2. 3. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning [Pharmalittle newsletter](https://www.statnews.com/signup/pharmalittle/) and the afternoon [Pharmalot newsletter](https://www.statnews.com/signup/pharmalot/). ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/09/GettyImages-2289339879-80x80.jpg) [John Fetterman’s post-stroke, politically problematic behaviors offer lessons about brain health on Capitol Hill](https://www.statnews.com/2026/09/10/john-fetterman-post-stroke-behavior-experts-see-neurological-changes/) 2. ![](https://www.statnews.com/wp-content/uploads/2022/06/AdamsTake_Illustration_MollyFerguson_061322-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon](https://www.statnews.com/2026/09/10/roivant-biotech-dealmaking-mosliciguat-origins/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/09/20260825_kaf_baugh_003-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Can AI fix health care? In the chaos of emergency rooms, the technology comes up short](https://www.statnews.com/2026/09/09/ai-healthcare-limitations-emergency-room-study-medical-scribe-impact/) 4. ![](https://www.statnews.com/wp-content/uploads/2020/12/AP_464867626358-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [What to expect from UniQure’s upcoming Huntington’s gene therapy readout ](https://www.statnews.com/2026/09/10/uniqure-huntingtons-gene-therapy-trial-readout/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/09/AdobeStock_312976841-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ARPA-H to invest $62 million to develop FDA-authorized AI to help treat heart failure](https://www.statnews.com/2026/09/09/arpa-h-advocate-program-autonomous-ai-bots-for-heart-failure/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/09/Lindsay_Clancy_Trial_8_1_1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Lindsay Clancy case exposes dangers of fragmented U.S. health system, experts say](https://www.statnews.com/2026/09/04/lindsay-clancy-health-care-silos-postpartum-care-failures/) 2. ![](https://www.statnews.com/wp-content/uploads/2018/10/STAT_Novartis02-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Novartis’ experimental cardiovascular drug fails a pivotal study](https://www.statnews.com/2026/09/04/novartis-therapy-pelacarsen-fails-cardiovascular-trial/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/01/heart-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation](https://www.statnews.com/2026/09/07/novo-nordisk-heart-studies-inflammation-ziltivekimab/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/09/AP23227774736501-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Recipients of gene-edited pig kidneys successfully receive human organs](https://www.statnews.com/2026/09/03/recipients-of-gene-edited-pig-kidneys-receive-human-organs/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/09/AdobeStock_188087817-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [After failure of Angelman syndrome drug, experts see hope in other experimental therapies](https://www.statnews.com/2026/09/04/angelman-syndrome-drug-ultragenyx-oak-hill-ionis/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot September 10, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Cancer medicines remain in short supply across the U.S., survey finds ](https://www.statnews.com/pharmalot/2026/09/10/cancer-medicines-remain-in-short-supply-across-the-united-states/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot September 9, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Pharmalittle: We’re reading about an AstraZeneca COPD win, the FDA filling key jobs, and more ](https://www.statnews.com/pharmalot/2026/09/09/astrazeneca-copd-win-fda-filling-key-jobs/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot September 8, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: FDA warns an API supplier about residue on walls, a corroded product line, and open-toed sandals ](https://www.statnews.com/pharmalot/2026/09/08/fda-warns-api-supplier-residue-corroded-production-line-sandals/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot September 8, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more ](https://www.statnews.com/pharmalot/2026/09/08/novartis-reports-second-trial-failure-novo-nordisk-setback/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot September 4, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more ](https://www.statnews.com/pharmalot/2026/09/04/pharmalittle-bristol-car-t-trial-pause-pfizer-offloads-shelved-candidate/) By [Jason Mast](https://www.statnews.com/staff/jason-mast/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Abivax has still not been acquired. What’s going on? ](https://www.statnews.com/2026/09/03/abivax-acquisition-target-replimune-fda/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Lindsay Clancy case exposes dangers of fragmented U.S. health system, experts say ](https://www.statnews.com/2026/09/04/lindsay-clancy-health-care-silos-postpartum-care-failures/) By [Tara Bannow](https://www.statnews.com/staff/tara-bannow/) 3. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Inhibrx claims first win for long-sought immunotherapy target ](https://www.statnews.com/2026/09/08/inhibrx-inbrx-106-ox40-immunotherapy-head-and-neck-cancer-hpv-positive/) By [Jason Mast](https://www.statnews.com/staff/jason-mast/) 4. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Seattle scientists launch $95 million AI biology effort ](https://www.s
## Related Clinical Research

- [Many physicians still accept pharma freebies and rely on sales reps, analysis finds](https://medichelpline.com/clinical-feed/stat-news-0-stat-the-gifts-from-pharma-companies-that-keep-on-giving.md)
- [Cardiac-targeted delivery strategies for advanced therapies in heart disease](https://medichelpline.com/clinical-feed/pubmed-42284133.md) (DOI: 10.1093/eurheartj/ehag432)
- [Neurocrine Biosciences: weighing benefit and risk for a rare-disease drug](https://medichelpline.com/clinical-feed/stat-news-2-stat-neurocrine-biosciences-and-the-delicate-balance-of-benefit-and-risk.md)
- [Which Exercises Best Target Blood Pressure, Blood Sugar, and Cholesterol in Metabolic Syndrome?](https://medichelpline.com/clinical-feed/medical-news-today-0-how-do-different-exercises-target-blood-pressure-blood-sugar-and-cholesterol.md)
- [Planetary Health Diet Linked to Lower Cardiovascular Risk in Postmenopausal Women](https://medichelpline.com/clinical-feed/medical-news-today-0-plant-based-planetary-health-diet-could-help-protect-heart-health.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.